Kura Oncology, Inc. (KURA)

Kura Oncology's stock has trended down by 4.46% in the past six months, with a 52-week range between $5.45 and $12.49. Key events impacting the stock include Q4 2025 earnings missing consensus estimates, the FDA approval of KOMZIFTI, promising darlifarnib combination data, participation in healthcare conferences, and a 1-for-35 reverse stock split on October 18, 2024.

There is no explicit indication of demand seasonality for Kura Oncology, Inc.'s products or services. Demand is primarily driven by medical necessity, disease prevalence, and regulatory approvals, rather than seasonal fluctuations.

Kura Oncology, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing precision medicines for cancer treatment. The company operates in the Healthcare sector, specifically in Biotechnology and Drug Discovery. Kura Oncology's pipeline targets cancer signaling pathways in hematologic malignancies and solid tumors. Its major products include KOMZIFTI (ziftomenib), an FDA-approved treatment for relapsed or refractory AML, darlifarnib (KO-2806), a farnesyl transferase inhibitor in Phase 1 trials, tipifarnib, a farnesyl transferase inhibitor previously in Phase 1/2 trial, and KO-7246, a menin inhibitor being explored for diabetes, cardiometabolic disorders and solid tumors.

Kura Oncology, Inc. is headquartered in San Diego, California, United States, and its sales are primarily generated within the United States.

Kura Oncology's brand reputation has been positively influenced by the FDA approval of KOMZIFTI, which established the company's first commercial product. This approval has been met with positive market feedback, emphasizing the safety and convenience of ziftomenib. Advancements in its pipeline, such as promising data for darlifarnib in renal cell carcinoma, further contribute to a positive scientific and clinical reputation.

Kura Oncology, Inc. has significant institutional ownership, with 217 institutional owners holding 84,711,902 shares. Major institutional shareholders include BlackRock, Inc., BVF Inc/il, Suvretta Capital Management, Llc, and Vanguard Group Inc. The ownership breakdown consists of approximately 73% institutions, 24.9% hedge funds, 1.53% individual insiders, and 0.588% general public.